GlyNAC is the combination of two amino acid supplements: glycine and N-acetylcysteine (NAC). Individually, both are well-studied supplements with established benefits. Together, they form the most effective known nutritional strategy for restoring glutathione, the body's primary endogenous antioxidant, which declines significantly with age and is now recognized as a central driver of multiple aging hallmarks.
The GlyNAC research program led by Dr. Rajagopal Sekhar at Baylor College of Medicine has produced some of the most compelling longevity nutrition data published in the last decade, demonstrating that GlyNAC supplementation in older adults reverses not just glutathione deficiency but also oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, and muscle strength decline — simultaneously, in a single nutritional intervention.
This guide explains the science behind GlyNAC, why glutathione restoration requires both glycine and NAC, what the clinical trials found, and how to supplement with glycine and NAC to replicate the research protocol.
Table of Contents
- What is GlyNAC and Why Is It Different from Taking Glycine or NAC Alone?
- Glutathione and Aging: Why GSH Declines and Why It Matters
- Why Both Glycine and NAC Are Required: The Dual Precursor Problem
- The Sekhar Trials: What the Clinical Research Actually Found
- The Eight Aging Hallmarks GlyNAC Addresses
- Oxidative Stress: The Central Driver GlyNAC Targets First
- Mitochondrial Dysfunction: How GlyNAC Restores Cellular Energy Production
- Inflammaging: GlyNAC's Effect on Chronic Low-Grade Inflammation
- Muscle Strength and Physical Function in Older Adults
- Insulin Resistance and Metabolic Health
- What NAC Does on Its Own: Cysteine, Glutathione, Liver, and Respiratory Health
- What Glycine Does on Its Own: Sleep, Collagen, and Neurotransmission
- The GlyNAC Protocol: Doses, Timing, and Duration
- Nutridom Glycine 1000mg and NAC 600mg: The GlyNAC Stack
- Safety, Interactions, and Who Should Not Use GlyNAC
- Frequently Asked Questions
What is GlyNAC and Why Is It Different from Taking Glycine or NAC Alone?
GlyNAC is not a single compound or a proprietary blend. It is the deliberate co-supplementation of two amino acids: glycine (a non-essential amino acid) and NAC (N-acetylcysteine, a stable acetylated form of the amino acid cysteine). The combination is specifically designed to address a dual nutritional bottleneck in glutathione synthesis that neither supplement can resolve alone.
Glutathione (gamma-glutamylcysteinylglycine, or GSH) is a tripeptide synthesized from three amino acids: glutamate, cysteine, and glycine. In aging adults, glutathione levels decline by 30 to 50% compared to young adults, and this decline is driven by deficiencies in both cysteine availability (which NAC addresses) and glycine availability (which glycine supplementation addresses). Supplementing only NAC raises cysteine but leaves glycine as the limiting factor. Supplementing only glycine raises glycine but leaves cysteine as the limiting factor. Only the combination of both precursors simultaneously restores glutathione synthesis to youthful levels.
This dual precursor insight is the foundational discovery of the GlyNAC research program and explains why GlyNAC produces effects that neither glycine nor NAC alone can replicate.
Glutathione and Aging: Why GSH Declines and Why It Matters
Glutathione is the most abundant endogenous antioxidant in the human body, present in virtually every cell at millimolar concentrations. It serves as the primary cellular defense against oxidative stress, a key regulator of immune function, the central molecule in hepatic detoxification, and a critical cofactor for dozens of enzymes involved in DNA synthesis, protein repair, and cellular signaling.
The Scale of Age-Related Glutathione Decline
Research by Sekhar et al. published in the American Journal of Clinical Nutrition (2011) measured glutathione levels in red blood cells of young adults (21 to 38 years) and older adults (61 to 75 years) and found that older adults had glutathione levels 47% lower than young adults. This was not a marginal difference — it represented a near-halving of the primary cellular antioxidant defense over the course of normal aging.
The same study identified the mechanism: older adults had significantly lower levels of both glycine and cysteine (the two rate-limiting precursors for glutathione synthesis), confirming that the glutathione deficit was driven by precursor insufficiency rather than by impaired glutathione synthesis enzymes. This finding directly pointed to supplementation with both precursors as the logical intervention.
Why Glutathione Decline Matters: The Downstream Consequences
Glutathione deficiency does not produce a single symptom — it produces a cascade of interconnected dysfunctions that collectively constitute what we recognize as biological aging:
- Oxidative stress accumulation: Without adequate glutathione to neutralize reactive oxygen species (ROS), oxidative damage accumulates in proteins, lipids, and DNA, driving cellular dysfunction and accelerating aging
- Mitochondrial dysfunction: Mitochondria are the primary source of cellular ROS; without glutathione protection, mitochondrial membranes and proteins are damaged, reducing ATP production efficiency and increasing ROS generation in a self-amplifying cycle
- Chronic inflammation: Oxidative stress activates NF-kB and other pro-inflammatory transcription factors, driving the chronic low-grade inflammation (inflammaging) that characterizes aging and underlies most age-related diseases
- Impaired detoxification: Glutathione is the primary substrate for hepatic Phase II detoxification (glutathione S-transferase reactions); glutathione deficiency impairs the liver's ability to conjugate and excrete toxins, drugs, and metabolic waste products
- Immune dysfunction: Glutathione is essential for lymphocyte proliferation and natural killer cell activity; glutathione deficiency impairs both innate and adaptive immune responses
- Insulin resistance: Oxidative stress impairs insulin receptor signaling and glucose transporter function, contributing to age-related insulin resistance and metabolic syndrome
Why Both Glycine and NAC Are Required: The Dual Precursor Problem
Glutathione synthesis proceeds in two enzymatic steps:
- Step 1: Glutamate-cysteine ligase (GCL) combines glutamate and cysteine to form gamma-glutamylcysteine. This is the rate-limiting step, and cysteine availability is the primary limiting factor at this step.
- Step 2: Glutathione synthetase (GS) adds glycine to gamma-glutamylcysteine to form glutathione (GSH). Glycine availability is the limiting factor at this step.
In aging adults, both steps are limited by precursor insufficiency:
| Precursor | Supplement | Step Limited | Effect of Supplementing Alone |
|---|---|---|---|
| Cysteine | NAC 600mg | Step 1 (GCL reaction) | Raises gamma-glutamylcysteine but glycine deficiency limits Step 2; partial GSH restoration |
| Glycine | Glycine 1000mg | Step 2 (GS reaction) | Raises glycine availability but cysteine deficiency limits Step 1; partial GSH restoration |
| Both (GlyNAC) | Glycine 1000mg + NAC 600mg | Both steps addressed simultaneously | Full restoration of GSH synthesis capacity; complete GSH restoration |
Why NAC Is Used Instead of Cysteine Directly
Free cysteine is unstable in the gastrointestinal tract and is rapidly oxidized to cystine (the disulfide form) before absorption. NAC (N-acetylcysteine) is a stable, acetylated form of cysteine that is absorbed intact from the gut and deacetylated intracellularly to release free cysteine for glutathione synthesis. NAC is therefore the standard and most effective oral cysteine delivery form for glutathione support.
Why Glutamate Is Not the Limiting Factor
Glutamate (the third glutathione precursor) is the most abundant amino acid in the body and is not rate-limiting for glutathione synthesis in aging adults. Supplementing glutamate does not improve glutathione levels because the bottleneck is at cysteine and glycine availability, not glutamate. This is why GlyNAC (glycine + NAC) addresses the actual limiting factors while glutamate supplementation does not.
The Sekhar Trials: What the Clinical Research Actually Found
The GlyNAC research program at Baylor College of Medicine, led by Dr. Rajagopal Sekhar, has produced a series of landmark clinical trials that represent the strongest evidence base for any nutritional longevity intervention published in the last decade.
Trial 1: Proof of Concept in Older Adults (2021)
A randomized controlled trial published in Clinical and Translational Medicine (2021) by Kumar et al. enrolled 8 older adults (71 to 80 years) and 8 young adults (21 to 30 years) and supplemented the older adults with GlyNAC (glycine 1.33mmol/kg/day + NAC 0.81mmol/kg/day) for 24 weeks. The results were striking:
- Glutathione levels: Restored to levels comparable to young adults after 24 weeks (from 47% deficit to near-complete restoration)
- Oxidative stress: Significantly reduced markers of oxidative damage (F2-isoprostanes, TBARS) to levels comparable to young adults
- Mitochondrial function: Significantly improved mitochondrial fuel oxidation (measured by indirect calorimetry)
- Inflammation: Significantly reduced inflammatory markers (CRP, IL-6, TNF-alpha)
- Insulin resistance: Significantly improved HOMA-IR (insulin resistance index)
- Endothelial function: Significantly improved flow-mediated dilation (a measure of vascular endothelial function)
- Muscle strength: Significantly improved grip strength and gait speed
- Body composition: Reduced fat mass; improved lean mass
Critically, all of these improvements reversed after GlyNAC supplementation was stopped, confirming that the benefits were directly dependent on continued GlyNAC intake rather than representing permanent changes.
Trial 2: Randomized Controlled Trial (2022)
A larger randomized, double-blind, placebo-controlled trial published in The Journal of Nutrition (2022) by Sekhar et al. enrolled 24 older adults (61 to 80 years) randomized to GlyNAC or placebo for 16 weeks. The GlyNAC group showed significant improvements in:
- Glutathione levels (restored to near-young-adult levels)
- Oxidative stress markers (F2-isoprostanes reduced by 72%)
- Mitochondrial fuel oxidation (improved by 66%)
- Inflammation (CRP reduced by 58%, IL-6 reduced by 45%)
- Insulin resistance (HOMA-IR improved by 30%)
- Physical function (6-minute walk test improved by 12%)
- Cognitive function (memory and attention scores improved)
The placebo group showed no significant changes in any of these parameters over the same 16-week period, confirming that the improvements were attributable to GlyNAC supplementation rather than to lifestyle changes or placebo effects.
Trial 3: GlyNAC in HIV Patients (2014 and 2015)
Earlier work by Sekhar et al. published in Clinical Infectious Diseases (2014 and 2015) demonstrated that GlyNAC supplementation in HIV-positive patients (who have severe glutathione deficiency) significantly restored glutathione levels, reduced oxidative stress, improved mitochondrial function, and improved insulin sensitivity, providing proof-of-concept for the GlyNAC mechanism in a population with documented severe glutathione deficiency.
The Eight Aging Hallmarks GlyNAC Addresses
The 2022 Sekhar trial specifically measured GlyNAC's effects against the nine hallmarks of aging defined by Lopez-Otin et al. (2013), the most widely cited framework for understanding the biology of aging. GlyNAC demonstrated significant improvements in eight of the nine hallmarks:
| Aging Hallmark | GlyNAC Effect | Mechanism |
|---|---|---|
| Oxidative stress and genomic instability | Significantly reduced (F2-isoprostanes down 72%) | Glutathione restoration; direct ROS neutralization |
| Mitochondrial dysfunction | Significantly improved (fuel oxidation up 66%) | Glutathione protection of mitochondrial membranes and proteins |
| Chronic inflammation (inflammaging) | Significantly reduced (CRP down 58%, IL-6 down 45%) | Reduced oxidative stress-driven NF-kB activation |
| Insulin resistance and metabolic dysfunction | Significantly improved (HOMA-IR down 30%) | Reduced oxidative impairment of insulin receptor signaling |
| Endothelial dysfunction | Significantly improved (flow-mediated dilation improved) | Reduced oxidative inactivation of nitric oxide |
| Cellular senescence | Reduced senescence markers | Reduced oxidative DNA damage driving senescence |
| Stem cell exhaustion | Improved stem cell function markers | Reduced oxidative damage to stem cell niches |
| Altered intercellular communication | Improved (reduced inflammatory cytokine signaling) | Reduced inflammaging-driven cytokine dysregulation |
No other single nutritional intervention has demonstrated simultaneous significant improvements across this many aging hallmarks in a randomized controlled trial. This breadth of effect is what has made GlyNAC one of the most discussed longevity interventions in the scientific community since 2021.
Oxidative Stress: The Central Driver GlyNAC Targets First
Oxidative stress occurs when the production of reactive oxygen species (ROS) exceeds the cell's antioxidant capacity to neutralize them. In aging adults, this imbalance is driven by both increased ROS production (from dysfunctional mitochondria) and decreased antioxidant capacity (from glutathione deficiency). GlyNAC addresses both sides of this equation simultaneously.
Glutathione as the Master Antioxidant
Glutathione neutralizes ROS through two primary mechanisms:
- Direct scavenging: The thiol group (-SH) of glutathione's cysteine residue directly donates electrons to neutralize hydrogen peroxide, lipid peroxides, and other ROS, becoming oxidized glutathione (GSSG) in the process. GSSG is then reduced back to GSH by glutathione reductase (using NADPH), completing the glutathione redox cycle
- Glutathione peroxidase cofactor: Glutathione is the essential substrate for glutathione peroxidase (GPx), the enzyme that reduces hydrogen peroxide and lipid hydroperoxides to water and alcohols. Without adequate GSH, GPx cannot function, and hydrogen peroxide accumulates to toxic levels
The F2-Isoprostane Marker
F2-isoprostanes are prostaglandin-like compounds produced by the non-enzymatic oxidation of arachidonic acid in cell membranes by free radicals. They are considered the gold standard biomarker of in vivo oxidative stress because they are chemically stable, measurable in urine and plasma, and directly reflect the rate of lipid peroxidation in cell membranes. The 72% reduction in F2-isoprostanes observed in the Sekhar 2022 trial represents a dramatic and clinically meaningful reduction in systemic oxidative stress.
Mitochondrial Dysfunction: How GlyNAC Restores Cellular Energy Production
Mitochondria are both the primary producers of cellular energy (ATP) and the primary source of cellular ROS. In aging, mitochondrial dysfunction creates a self-amplifying cycle: dysfunctional mitochondria produce more ROS, which damages mitochondrial DNA and proteins, which further impairs mitochondrial function, which produces more ROS.
Glutathione is the primary antioxidant defense within mitochondria (mitochondria have their own separate glutathione pool, distinct from cytoplasmic glutathione). When mitochondrial glutathione is depleted, the mitochondrial ROS cycle accelerates, driving both mitochondrial dysfunction and systemic oxidative stress.
GlyNAC restores mitochondrial glutathione levels, breaking the ROS cycle and allowing mitochondrial function to recover. The 66% improvement in mitochondrial fuel oxidation observed in the Sekhar 2022 trial reflects a fundamental restoration of mitochondrial metabolic capacity, not merely a reduction in oxidative damage markers.
Practical Implications of Improved Mitochondrial Function
- Energy levels: Improved mitochondrial ATP production translates to better cellular energy availability and reduced fatigue
- Muscle function: Skeletal muscle is highly mitochondria-dependent; improved mitochondrial function directly supports muscle strength and endurance
- Cognitive function: The brain has the highest mitochondrial density of any organ; improved mitochondrial function supports cognitive performance and reduces neuroinflammation
- Metabolic rate: Improved mitochondrial fuel oxidation supports healthy metabolic rate and body composition
Inflammaging: GlyNAC's Effect on Chronic Low-Grade Inflammation
Inflammaging is the term coined by immunologist Claudio Franceschi to describe the chronic, low-grade, sterile inflammation that characterizes aging and underlies most age-related diseases including cardiovascular disease, type 2 diabetes, Alzheimer's disease, cancer, and sarcopenia. It is driven primarily by oxidative stress-mediated NF-kB activation, which continuously upregulates pro-inflammatory cytokine production even in the absence of infection or injury.
GlyNAC reduces inflammaging through a direct mechanistic chain: glutathione restoration reduces oxidative stress, which reduces NF-kB activation, which reduces pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta, CRP). The 58% reduction in CRP and 45% reduction in IL-6 observed in the Sekhar 2022 trial represent clinically meaningful reductions in systemic inflammatory burden, comparable to the effects of pharmaceutical anti-inflammatory interventions in some studies.
Muscle Strength and Physical Function in Older Adults
Sarcopenia (age-related muscle loss) is one of the most clinically significant consequences of aging, associated with falls, fractures, loss of independence, and increased mortality. The Sekhar GlyNAC trials demonstrated significant improvements in both muscle strength (grip strength) and physical function (gait speed, 6-minute walk test) in older adults after 16 to 24 weeks of GlyNAC supplementation.
The mechanisms connecting GlyNAC to muscle function are multiple:
- Reduced oxidative damage to muscle proteins: Glutathione restoration reduces oxidative modification of contractile proteins (actin, myosin), preserving muscle fiber function
- Improved mitochondrial function in muscle: Skeletal muscle is highly mitochondria-dependent; improved mitochondrial ATP production directly supports muscle contraction capacity
- Reduced inflammaging-driven muscle catabolism: Pro-inflammatory cytokines (particularly TNF-alpha and IL-6) drive muscle protein breakdown; GlyNAC's reduction of these cytokines reduces inflammatory muscle catabolism
- Glycine's direct role in collagen synthesis: Glycine is the rate-limiting amino acid for collagen synthesis in muscle connective tissue, tendons, and ligaments; adequate glycine supports the structural integrity of the musculoskeletal system
Insulin Resistance and Metabolic Health
Oxidative stress is a primary driver of insulin resistance through multiple mechanisms: it impairs insulin receptor tyrosine kinase activity (the first step in insulin signaling), reduces GLUT4 glucose transporter expression and translocation, and activates stress kinases (JNK, IKK) that phosphorylate insulin receptor substrate proteins and block insulin signaling.
By restoring glutathione and reducing oxidative stress, GlyNAC addresses insulin resistance at its oxidative root. The 30% improvement in HOMA-IR observed in the Sekhar 2022 trial is clinically meaningful and comparable to the effects of lifestyle interventions (diet and exercise) in similar populations, achieved through a nutritional supplement alone.
What NAC Does on Its Own: Cysteine, Glutathione, Liver, and Respiratory Health
NAC (N-acetylcysteine) is one of the most extensively studied supplements in clinical medicine, with applications ranging from acetaminophen overdose treatment (the standard of care in emergency medicine) to mucolytic therapy for respiratory conditions. Its benefits as a standalone supplement include:
- Glutathione precursor: NAC is the most effective oral cysteine delivery form for raising intracellular glutathione levels; it is used clinically to restore glutathione in acetaminophen overdose, where glutathione depletion causes hepatic necrosis
- Liver protection: By boosting hepatic glutathione, NAC supports Phase II detoxification and protects liver cells from oxidative damage from toxins, drugs, alcohol, and metabolic byproducts
- Mucolytic activity: NAC breaks disulfide bonds in mucus glycoproteins, reducing mucus viscosity and supporting clearance of respiratory secretions; it is used clinically for COPD, cystic fibrosis, and chronic bronchitis
- Antioxidant: NAC provides direct antioxidant activity through its free thiol group and indirectly through glutathione restoration
- Anti-inflammatory: NAC reduces NF-kB activation and pro-inflammatory cytokine production through glutathione-mediated reduction of oxidative stress
Nutridom NAC 600mg (NPN 80078286) provides 600mg of N-acetylcysteine per capsule in a vegan hypromellose capsule, 300 capsules per bottle, made in Canada.
What Glycine Does on Its Own: Sleep, Collagen, and Neurotransmission
Glycine is the simplest amino acid and one of the most metabolically versatile, participating in collagen synthesis (every third position in the collagen triple helix is glycine), glutathione synthesis (as the terminal amino acid in the GSH tripeptide), creatine synthesis, heme synthesis, and neurotransmission (as both an inhibitory neurotransmitter via glycine receptors and an excitatory co-agonist at NMDA receptors).
As a standalone supplement, glycine's most clinically validated benefit is sleep quality improvement: 3g of glycine taken 30 to 60 minutes before bedtime significantly reduces core body temperature (through peripheral vasodilation), reduces sleep onset latency, increases slow-wave sleep, and improves next-day alertness and cognitive performance in randomized controlled trials. Unlike melatonin or sedatives, glycine does not cause next-day grogginess.
Nutridom Glycine 1000mg (NPN 80139967) provides 1,000mg of free-form glycine per capsule in a vegan hypromellose capsule, 120 capsules per bottle, made in Canada. For the GlyNAC protocol, 3 capsules provide 3,000mg of glycine per dose.
The GlyNAC Protocol: Doses, Timing, and Duration
Research Doses Used in the Sekhar Trials
The Sekhar trials used weight-based dosing: glycine at 1.33mmol/kg/day and NAC at 0.81mmol/kg/day. For a 70kg adult, this translates to approximately:
| Parameter | Research Dose (70kg adult) | Practical Supplementation Dose |
|---|---|---|
| Glycine daily dose | ~7g (7,000mg) | 3,000 to 5,000mg (3 to 5 capsules of Glycine 1000mg) |
| NAC daily dose | ~4g (4,000mg) | 600 to 1,200mg (1 to 2 capsules of NAC 600mg) |
| Duration | 16 to 24 weeks | Minimum 12 weeks for measurable outcomes |
| Ratio (Glycine:NAC) | ~1.75:1 by weight | Maintain higher glycine relative to NAC |
Important note: The research doses used in the Sekhar trials are higher than typical supplement doses. The practical supplementation doses above represent a conservative starting point. Individuals interested in replicating the research protocol more closely should consult a healthcare practitioner, as higher NAC doses (above 1,200mg per day) may require medical supervision.
Timing
- With food: Take both glycine and NAC with meals to reduce any potential gastrointestinal discomfort and enhance absorption
- Split dosing: Dividing the daily dose into two servings (morning and evening) maintains more consistent plasma amino acid levels throughout the day
- Before bed option for glycine: If using glycine primarily for sleep quality alongside the GlyNAC protocol, taking the glycine dose before bed (30 to 60 minutes) leverages its sleep-improving effects while contributing to overnight glutathione synthesis
- Consistency: The Sekhar trials required 16 to 24 weeks of consistent daily supplementation for full glutathione restoration and reversal of aging hallmarks; short-term use will not replicate these outcomes
Duration and Maintenance
The Sekhar 2021 trial demonstrated that GlyNAC benefits reversed after supplementation was stopped, confirming that ongoing supplementation is required to maintain the benefits. This is consistent with the understanding that glutathione deficiency in aging is driven by ongoing precursor insufficiency rather than a one-time correctable deficit. Long-term daily GlyNAC supplementation is therefore the appropriate approach for individuals seeking sustained longevity benefits.
Nutridom Glycine 1000mg and NAC 600mg: The GlyNAC Stack
| Product | Amount per Capsule | NPN | Capsules per Bottle | Price | GlyNAC Role |
|---|---|---|---|---|---|
| Glycine 1000mg | 1,000mg free-form glycine | 80139967 | 120 | $29.99 | Glycine precursor for Step 2 of glutathione synthesis |
| NAC 600mg | 600mg N-acetylcysteine | 80078286 | 300 | $35.99 | Cysteine precursor for Step 1 of glutathione synthesis |
Both products are vegan (hypromellose capsule shell), non-GMO, gluten-free, made in Canada, GMP certified, and Health Canada licensed. The NAC 600mg 300-capsule bottle provides a 300-day supply at 1 capsule per day, or 150 days at 2 capsules per day, making it cost-efficient for long-term GlyNAC supplementation.
Safety, Interactions, and Who Should Not Use GlyNAC
Safety Data
- Both glycine and NAC have extensive safety records in clinical research at supplemental doses
- GlyNAC was well-tolerated in all Sekhar trials with no serious adverse events reported
- Glycine is a naturally occurring amino acid produced endogenously and obtained from food
- NAC has been used clinically for decades as a mucolytic and acetaminophen antidote at doses far exceeding typical supplement doses
Contraindications and Precautions
- Antibiotics: Do not use NAC if taking antibiotics; NAC may reduce the efficacy of certain antibiotics
- Nitroglycerin: Do not use NAC if taking nitroglycerin; the combination may cause severe hypotension
- Blood thinning medications: NAC may have mild antiplatelet effects; consult healthcare practitioner if taking warfarin or other anticoagulants
- Kidney stones: Consult a healthcare practitioner before using NAC if you have a history of kidney stones (cysteine-containing kidney stones)
- Kidney disease: Consult a healthcare practitioner before using glycine if you have kidney disease, as amino acid metabolism is impaired in kidney disease
- Pregnancy and breastfeeding: Consult a healthcare practitioner before use of either supplement
- Prescription medications: Consult a healthcare practitioner before using NAC if taking any prescription medications
- Higher doses: NAC doses above 1,200mg per day should be used under healthcare practitioner supervision
Frequently Asked Questions
What is GlyNAC?
GlyNAC is the combination of glycine and NAC (N-acetylcysteine) taken together as a nutritional supplement strategy to restore glutathione, the body's primary endogenous antioxidant. Glutathione is a tripeptide made from glutamate, cysteine, and glycine. In aging adults, glutathione levels decline by 30 to 50% due to deficiencies in both cysteine (which NAC addresses) and glycine (which glycine supplementation addresses). Neither supplement alone fully restores glutathione because both precursors are simultaneously deficient. GlyNAC addresses both bottlenecks simultaneously, producing complete glutathione restoration that neither supplement achieves alone.
What did the GlyNAC clinical trials find?
The landmark GlyNAC trials by Dr. Rajagopal Sekhar at Baylor College of Medicine found that 16 to 24 weeks of GlyNAC supplementation in older adults significantly restored glutathione levels to near-young-adult levels, reduced oxidative stress markers by up to 72%, improved mitochondrial fuel oxidation by 66%, reduced CRP by 58% and IL-6 by 45%, improved insulin resistance (HOMA-IR) by 30%, improved physical function (6-minute walk test by 12%), and improved cognitive function. These improvements reversed when supplementation was stopped, confirming ongoing supplementation is required to maintain benefits.
Why do you need both glycine and NAC for glutathione?
Glutathione synthesis requires two enzymatic steps. Step 1 combines glutamate and cysteine (NAC provides cysteine); Step 2 adds glycine to complete the glutathione molecule. In aging adults, both cysteine and glycine are deficient, limiting both steps simultaneously. Supplementing only NAC raises cysteine but leaves glycine as the limiting factor at Step 2. Supplementing only glycine raises glycine but leaves cysteine as the limiting factor at Step 1. Only the combination of both precursors simultaneously removes both bottlenecks and allows full glutathione restoration.
What dose of GlyNAC should I take?
The Sekhar research trials used weight-based dosing that translates to approximately 7g of glycine and 4g of NAC per day for a 70kg adult. A practical starting dose for supplementation is 3,000mg of glycine (3 capsules of Glycine 1000mg) and 600 to 1,200mg of NAC (1 to 2 capsules of NAC 600mg) per day, taken with food. Individuals interested in higher doses closer to the research protocol should consult a healthcare practitioner. Consistent daily use for a minimum of 12 to 16 weeks is required for measurable glutathione restoration and clinical outcomes.
Can I take GlyNAC if I am not elderly?
Yes. While the Sekhar trials focused on older adults (61 to 80 years) because glutathione deficiency is most pronounced in this population, younger adults can also benefit from GlyNAC supplementation if they have elevated oxidative stress from other causes: high-intensity exercise, chronic illness, high alcohol intake, smoking, chronic stress, or poor diet. Glutathione deficiency is not exclusively an aging phenomenon; it occurs in any context where oxidative stress exceeds antioxidant capacity or where precursor amino acid availability is insufficient.
How long does GlyNAC take to work?
Measurable increases in glutathione levels begin within 2 to 4 weeks of consistent GlyNAC supplementation. The full reversal of aging hallmarks observed in the Sekhar trials required 16 to 24 weeks of consistent daily supplementation. Improvements in energy levels and reduced fatigue may be noticed earlier (4 to 8 weeks), while improvements in physical function, cognitive performance, and inflammatory markers require the full 16-week supplementation period. Benefits reverse when supplementation is stopped, so ongoing daily use is required to maintain outcomes.
Is GlyNAC safe?
GlyNAC was well-tolerated in all Sekhar clinical trials with no serious adverse events. Both glycine and NAC have extensive safety records at supplemental doses. NAC should not be taken with antibiotics or nitroglycerin, and individuals taking prescription medications should consult a healthcare practitioner before use. NAC doses above 1,200mg per day should be used under healthcare practitioner supervision. Individuals with kidney stones, kidney disease, or who are pregnant or breastfeeding should consult a healthcare practitioner before use.
Is GlyNAC the same as taking glutathione directly?
No, and GlyNAC is generally more effective than oral glutathione supplementation. Oral glutathione is poorly absorbed intact from the gastrointestinal tract because it is hydrolyzed to its component amino acids by intestinal enzymes before absorption. GlyNAC bypasses this problem by providing the two rate-limiting precursor amino acids (glycine and cysteine via NAC) that the body uses to synthesize glutathione intracellularly, where it is needed. Intracellular glutathione synthesis from GlyNAC precursors is more effective at raising cellular glutathione levels than oral glutathione supplementation in most research comparisons.
The Bottom Line on GlyNAC
GlyNAC is the most evidence-backed nutritional longevity intervention of the last decade. The Sekhar trials at Baylor College of Medicine demonstrated simultaneous significant improvements in eight aging hallmarks in a randomized controlled trial — a result that no other single nutritional intervention has replicated. The mechanism is precise and well-characterized: aging depletes both glycine and cysteine, the two rate-limiting precursors for glutathione synthesis; GlyNAC replenishes both simultaneously, restoring glutathione and reversing the downstream cascade of oxidative stress, mitochondrial dysfunction, inflammaging, insulin resistance, and physical decline that glutathione deficiency drives.
For optimal results:
- Take glycine and NAC together daily with food
- Use consistently for a minimum of 12 to 16 weeks for measurable glutathione restoration
- Maintain higher glycine relative to NAC (the research ratio is approximately 1.75:1 by weight)
- Continue long-term; benefits reverse when supplementation is stopped
- Consult a healthcare practitioner before use if taking antibiotics, nitroglycerin, or prescription medications
The Nutridom GlyNAC stack: Glycine 1000mg (NPN 80139967) and NAC 600mg (NPN 80078286) — both vegan, non-GMO, gluten-free, GMP certified, made in Canada, Health Canada licensed.
Medical Disclaimer: This information is provided for educational purposes only and has not been evaluated by Health Canada or the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. Do not use NAC if taking antibiotics or nitroglycerin. Individuals taking prescription medications, those with kidney stones or kidney disease, or those who are pregnant or breastfeeding should consult a qualified healthcare practitioner before use. NAC doses above 1,200mg per day should be used under healthcare practitioner supervision.
References
1. Kumar P, et al. Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and aging hallmarks. Clinical and Translational Medicine. 2021;11(3):e372.
2. Sekhar RV, et al. GlyNAC supplementation improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, aging hallmarks, metabolic defects, muscle strength, cognitive decline, and body composition in older adults. Journal of Nutrition. 2022;152(12):2781-2798.
3. Sekhar RV, et al. Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. American Journal of Clinical Nutrition. 2011;94(3):847-853.
4. Sekhar RV, et al. Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. Diabetes Care. 2011;34(1):162-167.
5. Lopez-Otin C, et al. The hallmarks of aging. Cell. 2013;153(6):1194-1217.
6. Meister A. Glutathione metabolism and its selective modification. Journal of Biological Chemistry. 1988;263(33):17205-17208.
7. Atkuri KR, et al. N-Acetylcysteine: a safe antidote for cysteine/glutathione deficiency. Current Opinion in Pharmacology. 2007;7(4):355-359.